223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence
Pioglitazone (PIO) therapy results in a ∼60% resolution of NASH in patients with prediabetes or T2DM. However, the effects of treatment discontinuation have not been carefully examined. To this end, we assessed plasma aminotransferases (LFTs) after study drug discontinuation among patients who had c...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 68 |
| creator | BRIL, FERNANDO LOMONACO, ROMINA KALAVALAPALLI, SRILAXMI LAI, JINPING CUSI, KENNETH |
| description | Pioglitazone (PIO) therapy results in a ∼60% resolution of NASH in patients with prediabetes or T2DM. However, the effects of treatment discontinuation have not been carefully examined. To this end, we assessed plasma aminotransferases (LFTs) after study drug discontinuation among patients who had completed 36 months (n=63) of our randomized, controlled trial (RCT) of PIO for NASH (Cusi, et al. Ann Intern Med 2016). This was an 18 month RCT of PIO 45mg QD vs. placebo (and dietary counseling in all), followed by 18 months of open label PIO. We retrospectively assessed LFTs for 18 months following study discontinuation. PIO normalized plasma ALT, an indicator of hepatocyte injury in NASH, within 3 months of therapy initiation (from 61±5 to 35±2 U/L; p |
| doi_str_mv | 10.2337/db19-223-OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2248403176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248403176</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1066-12609ad7e56a9e656d0f8f0a58835d0b0cbd98683fd9f372254994703192d8ea3</originalsourceid><addsrcrecordid>eNotkE1LAzEYhIMoWKsn_0DAiyKr-dhNNt5K_ahQ2tIqeFvSJGtT1k1Nsohe_OumrMzhncMzA-8AcI7RDaGU3-o1FhkhNJsvD8AACyoySvjbIRgghEmGueDH4CSELUKIJQ3Ab0_fwYV1742N8se1Bt7boFwbbdvJaF0LbQsXyZk2Bvhl4wbOXCsb5TausQquopHRbcwuIdEGeDkbrSZX8DnAUQhOWRmN7mOp18hg4NKoznvTKnMKjmrZBHP2f4fg9fHhZTzJpvOn5_FomimMGMswYUhIzU3BpDCsYBrVZY1kUZa00GiN1FqLkpW01qKmnJAiFyLniGJBdGkkHYKLvnfn3WdnQqy2rvPpiVARkpd5IjlL1HVPKe9C8Kaudt5-SP9dYVTtF672C6cEreZL-gdZum5R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248403176</pqid></control><display><type>article</type><title>223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>BRIL, FERNANDO ; LOMONACO, ROMINA ; KALAVALAPALLI, SRILAXMI ; LAI, JINPING ; CUSI, KENNETH</creator><creatorcontrib>BRIL, FERNANDO ; LOMONACO, ROMINA ; KALAVALAPALLI, SRILAXMI ; LAI, JINPING ; CUSI, KENNETH</creatorcontrib><description>Pioglitazone (PIO) therapy results in a ∼60% resolution of NASH in patients with prediabetes or T2DM. However, the effects of treatment discontinuation have not been carefully examined. To this end, we assessed plasma aminotransferases (LFTs) after study drug discontinuation among patients who had completed 36 months (n=63) of our randomized, controlled trial (RCT) of PIO for NASH (Cusi, et al. Ann Intern Med 2016). This was an 18 month RCT of PIO 45mg QD vs. placebo (and dietary counseling in all), followed by 18 months of open label PIO. We retrospectively assessed LFTs for 18 months following study discontinuation. PIO normalized plasma ALT, an indicator of hepatocyte injury in NASH, within 3 months of therapy initiation (from 61±5 to 35±2 U/L; p<0.001) and for the duration of treatment (Figure 1).
However, PIO discontinuation resulted in a rapid rebound of LFTs after 3 months (from 30±2 to 42±7 U/L, p=0.02), and continued to increase over time, reaching the highest levels 18 months after discontinuation (59±12 U/L, p<0.001 vs. end of the trial). Plasma AST followed a similar pattern during treatment and after discontinuation.
Conclusion: PIO rapidly normalizes LFTs in NASH and improves liver histology, but its discontinuation results in an abrupt increase in LFTs, likely reflecting NASH recurrence. Therefore, PIO therapy for NASH should be considered as a long-term management approach.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db19-223-OR</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Pioglitazone</subject><ispartof>Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1066-12609ad7e56a9e656d0f8f0a58835d0b0cbd98683fd9f372254994703192d8ea3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>BRIL, FERNANDO</creatorcontrib><creatorcontrib>LOMONACO, ROMINA</creatorcontrib><creatorcontrib>KALAVALAPALLI, SRILAXMI</creatorcontrib><creatorcontrib>LAI, JINPING</creatorcontrib><creatorcontrib>CUSI, KENNETH</creatorcontrib><title>223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence</title><title>Diabetes (New York, N.Y.)</title><description>Pioglitazone (PIO) therapy results in a ∼60% resolution of NASH in patients with prediabetes or T2DM. However, the effects of treatment discontinuation have not been carefully examined. To this end, we assessed plasma aminotransferases (LFTs) after study drug discontinuation among patients who had completed 36 months (n=63) of our randomized, controlled trial (RCT) of PIO for NASH (Cusi, et al. Ann Intern Med 2016). This was an 18 month RCT of PIO 45mg QD vs. placebo (and dietary counseling in all), followed by 18 months of open label PIO. We retrospectively assessed LFTs for 18 months following study discontinuation. PIO normalized plasma ALT, an indicator of hepatocyte injury in NASH, within 3 months of therapy initiation (from 61±5 to 35±2 U/L; p<0.001) and for the duration of treatment (Figure 1).
However, PIO discontinuation resulted in a rapid rebound of LFTs after 3 months (from 30±2 to 42±7 U/L, p=0.02), and continued to increase over time, reaching the highest levels 18 months after discontinuation (59±12 U/L, p<0.001 vs. end of the trial). Plasma AST followed a similar pattern during treatment and after discontinuation.
Conclusion: PIO rapidly normalizes LFTs in NASH and improves liver histology, but its discontinuation results in an abrupt increase in LFTs, likely reflecting NASH recurrence. Therefore, PIO therapy for NASH should be considered as a long-term management approach.</description><subject>Pioglitazone</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkE1LAzEYhIMoWKsn_0DAiyKr-dhNNt5K_ahQ2tIqeFvSJGtT1k1Nsohe_OumrMzhncMzA-8AcI7RDaGU3-o1FhkhNJsvD8AACyoySvjbIRgghEmGueDH4CSELUKIJQ3Ab0_fwYV1742N8se1Bt7boFwbbdvJaF0LbQsXyZk2Bvhl4wbOXCsb5TausQquopHRbcwuIdEGeDkbrSZX8DnAUQhOWRmN7mOp18hg4NKoznvTKnMKjmrZBHP2f4fg9fHhZTzJpvOn5_FomimMGMswYUhIzU3BpDCsYBrVZY1kUZa00GiN1FqLkpW01qKmnJAiFyLniGJBdGkkHYKLvnfn3WdnQqy2rvPpiVARkpd5IjlL1HVPKe9C8Kaudt5-SP9dYVTtF672C6cEreZL-gdZum5R</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>BRIL, FERNANDO</creator><creator>LOMONACO, ROMINA</creator><creator>KALAVALAPALLI, SRILAXMI</creator><creator>LAI, JINPING</creator><creator>CUSI, KENNETH</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20190601</creationdate><title>223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence</title><author>BRIL, FERNANDO ; LOMONACO, ROMINA ; KALAVALAPALLI, SRILAXMI ; LAI, JINPING ; CUSI, KENNETH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1066-12609ad7e56a9e656d0f8f0a58835d0b0cbd98683fd9f372254994703192d8ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Pioglitazone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BRIL, FERNANDO</creatorcontrib><creatorcontrib>LOMONACO, ROMINA</creatorcontrib><creatorcontrib>KALAVALAPALLI, SRILAXMI</creatorcontrib><creatorcontrib>LAI, JINPING</creatorcontrib><creatorcontrib>CUSI, KENNETH</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BRIL, FERNANDO</au><au>LOMONACO, ROMINA</au><au>KALAVALAPALLI, SRILAXMI</au><au>LAI, JINPING</au><au>CUSI, KENNETH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2019-06-01</date><risdate>2019</risdate><volume>68</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Pioglitazone (PIO) therapy results in a ∼60% resolution of NASH in patients with prediabetes or T2DM. However, the effects of treatment discontinuation have not been carefully examined. To this end, we assessed plasma aminotransferases (LFTs) after study drug discontinuation among patients who had completed 36 months (n=63) of our randomized, controlled trial (RCT) of PIO for NASH (Cusi, et al. Ann Intern Med 2016). This was an 18 month RCT of PIO 45mg QD vs. placebo (and dietary counseling in all), followed by 18 months of open label PIO. We retrospectively assessed LFTs for 18 months following study discontinuation. PIO normalized plasma ALT, an indicator of hepatocyte injury in NASH, within 3 months of therapy initiation (from 61±5 to 35±2 U/L; p<0.001) and for the duration of treatment (Figure 1).
However, PIO discontinuation resulted in a rapid rebound of LFTs after 3 months (from 30±2 to 42±7 U/L, p=0.02), and continued to increase over time, reaching the highest levels 18 months after discontinuation (59±12 U/L, p<0.001 vs. end of the trial). Plasma AST followed a similar pattern during treatment and after discontinuation.
Conclusion: PIO rapidly normalizes LFTs in NASH and improves liver histology, but its discontinuation results in an abrupt increase in LFTs, likely reflecting NASH recurrence. Therefore, PIO therapy for NASH should be considered as a long-term management approach.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db19-223-OR</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2248403176 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Pioglitazone |
| title | 223-OR: Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated with Disease Recurrence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A23%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=223-OR:%20Pioglitazone%20Discontinuation%20in%20Patients%20with%20Nonalcoholic%20Steatohepatitis%20(NASH)%20Is%20Associated%20with%20Disease%20Recurrence&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=BRIL,%20FERNANDO&rft.date=2019-06-01&rft.volume=68&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db19-223-OR&rft_dat=%3Cproquest_cross%3E2248403176%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248403176&rft_id=info:pmid/&rfr_iscdi=true |